Illumina, Inc. (NASDAQ:ILMN) Receives $129.69 Average Price Target from Analysts

Illumina, Inc. (NASDAQ:ILMN) has been given an average recommendation of “Hold” by the eighteen ratings firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $129.6875.

ILMN has been the topic of a number of recent research reports. Wall Street Zen raised Illumina from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 14th. Zacks Research downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 31st. Canaccord Genuity Group raised their target price on Illumina from $130.00 to $150.00 and gave the stock a “hold” rating in a research note on Monday, January 26th. Barclays lifted their price target on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Finally, Stifel Nicolaus boosted their price target on shares of Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th.

Illumina Stock Up 0.2%

ILMN stock opened at $126.20 on Friday. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55. The firm has a 50-day moving average of $129.71 and a two-hundred day moving average of $121.36. Illumina has a 12 month low of $68.70 and a 12 month high of $155.53. The company has a market cap of $19.30 billion, a price-to-earnings ratio of 23.16, a PEG ratio of 2.41 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.09. The business had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, analysts forecast that Illumina will post 4.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the transaction, the senior vice president directly owned 16,321 shares in the company, valued at $1,896,173.78. The trade was a 12.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 2.60% of the stock is owned by company insiders.

Institutional Trading of Illumina

Several institutional investors have recently made changes to their positions in ILMN. MassMutual Private Wealth & Trust FSB grew its position in Illumina by 7.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock worth $142,000 after acquiring an additional 79 shares during the period. HighPoint Advisor Group LLC raised its position in Illumina by 3.7% in the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after purchasing an additional 80 shares during the period. Toronto Dominion Bank lifted its stake in shares of Illumina by 0.3% in the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock valued at $4,407,000 after purchasing an additional 92 shares during the last quarter. Assetmark Inc. lifted its stake in shares of Illumina by 10.2% in the 3rd quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock valued at $99,000 after purchasing an additional 96 shares during the last quarter. Finally, Panagora Asset Management Inc. grew its holdings in shares of Illumina by 3.9% during the 4th quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock worth $333,000 after purchasing an additional 96 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.